Synergy Pharmaceuticals Inc

Type: Company
Name: Synergy Pharmaceuticals Inc
First reported Oct 15 2014 - Updated Oct 16 2014 - 3 reports

ContraVir Pharmaceuticals Selects Pharmaceutical Product Development to Manage Phase 2b Study of Lead Antiviral FV-100 for Treating Shingles

EDISON, N.J., Oct. 16, 2014 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has entered into an agreement ... [Published TickerTech.com - Oct 16 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

SYNERGY PHARMACEUTICALS : to Present Additional Positive Phase 2b Study Results for Plecanatide in Patients with Irritable Bowel Syndrome with...

Synergy Pharmaceuticals to Present Additional Positive Phase 2b Study Results for Plecanatide in Patients with Irritable Bowel Syndrome with Constipation at ACG 2014 Annual Scientific MeetingBy a News Reporter-Staff News Editor at Pharma Business Week ... [Published 4 Traders - Oct 16 2014]
First reported Oct 10 2014 - Updated Oct 10 2014 - 1 reports

Synergy Pharmaceuticals : to Present Phase 2b Study Results for Plecanatide in Patients with IBS-C at ACG Annual Scientific Meeting

Synergy Pharmaceuticals said that it will present additional positive data from a phase 2b study assessing plecanatide's efficacy and safety in patients with irritable bowel syndrome with constipation (IBS-C).In its release, Synergy said that the data ... [Published 4 Traders - Oct 10 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 2 reports

Synergy Pharmaceuticals to Present Additional Positive Phase 2b Stu...

Synergy Pharmaceuticals to Present Additional Positive Phase 2b Study Results for Plecanatide in Patients with Irritable Bowel Syndrome with Constipation at ACG 2014 Annual Scientific MeetingOct. 07, 2014 Business Editors/Medical EditorsNEW YORK--(BUSINESS ... [Published Finwin - Oct 07 2014]
First reported Sep 25 2014 - Updated Sep 25 2014 - 1 reports

SYNERGY PHARMACEUTICALS : Reaches Halfway Mark for Second Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation

By a News Reporter-Staff News Editor at Pharma Business Week -- Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced that it has reached the halfway mark for total enrollment in the second pivotal phase 3 trial of plecanatide in patients with chronic ... [Published 4 Traders - Sep 25 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 4 reports

Synergy Pharma Reaches Halfway Mark For Second Phase 3 Trial Of Plecanatide

Synergy Pharmaceuticals Inc. (SGYP: Quote) announced that it has reached the halfway mark for total enrollment in the second pivotal phase 3 trial of plecanatide in patients with chronic idiopathic constipation or CIC.The trial is currently being conducted ... [Published RTTNews.com - Sep 18 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Synergy Pharmaceuticals Now Covered by Cowen and Company (SGYP)

Equities research analysts at Cowen and Company assumed coverage on shares of Synergy Pharmaceuticals (NASDAQ:SGYP) Synergy Pharmaceuticals (NASDAQ:SGYP) traded down 0.56% during mid-day trading on Friday, hitting $3.58. The stock had a trading volume ... [Published American Banking News - Stock Ratings - Sep 12 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

Synergy Pharmaceuticals Reports Second Quarter and First Half 2014 Financial Results

NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Reports Second Quarter and First Half 2014 Financial Results ... [Published Business Wire Health News - Aug 11 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

Synergy Pharmaceuticals to Present at Canaccord Genuity Growth Conference

NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals to Present at Canaccord Genuity Growth Conference ... [Published Business Wire Health News - Aug 06 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 2 reports

Synergy Pharmaceuticals Reaches Halfway Mark for the First Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation

NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Reaches Halfway Mark for the First Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation ... [Published Business Wire Science: Science News - Jul 14 2014]
First reported May 15 2014 - Updated May 15 2014 - 4 reports

Synergy Pharmaceuticals’ Chairman and CEO, Dr. Gary S. Jacob, Awarded Honorary Degree by the University of Missouri – St. Louis

NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals’ Chairman and CEO, Dr. Gary S. Jacob, Awarded Honorary Degree by the University of Missouri – St. Louis ... [Published Business Wire Photo/Multimedia News - May 15 2014]
First reported May 13 2014 - Updated May 13 2014 - 3 reports

Synergy Pharmaceuticals Reports First Quarter 2014 Financial Results: Cash and Investments Increase to $70.6 million as of March 31, 2014

NEW YORK--(EON: Enhanced Online News)--Synergy Pharmaceuticals Reports First Quarter 2014 Financial Results: Cash and Investments Increase to $70.6 million as of March 31, 2014 ... [Published EON Business - May 13 2014]

Quotes

Steve Matthews and Craig Torres of Bloomberg report, " Bullard Says Fed Should Consider Delay in Ending QE " :
James Sapirstein, chief executive officer of ContraVir, commented, "Given the positive results FV-100 has shown in early clinical studies, we look forward to initiating the Phase 2b trial and working with PPD to advance our differentiated product. It was important for ContraVir to select a CRO with the skills and experience to complete our Phase 2b study efficiently, while enabling us to further explore FV-100's potential to address this significant medical need."
The oral presentation titled, "Plecanatide, a Novel Uroguanylin Analog: a 12-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate Efficacy and Safety in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)" (Paper # 14) will be presented by Philip B Miner Jr...
...of ContraVir and seize upon the significant potential of FV-100," stated James Sapirstein , chief executive officer of ContraVir Pharmaceuticals. "Not only are we now capitalized to initiate the Phase 2b clinical trial of FV-100 in shingles, but we are also well positioned to target additional opportunities to add to our pipeline and build ContraVir as a multifaceted antiviral company."

More Content

All (41) | News (19) | Reports (0) | Blogs (22) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Fed Prepping Markets For More QE? [Published Seeking Alpha - 15 hours ago]
Synthetic Biologics fills irritable bowel syndr... [Published Center Watch - Oct 17 2014]
ContraVir Pharmaceuticals Selects Pharmaceutica... [Published TickerTech.com - Oct 16 2014]
SYNERGY PHARMACEUTICALS : to Present Additional... [Published 4 Traders - Oct 16 2014]
ContraVir Pharmaceuticals Closes $9M Financing [Published Citybizlist - Oct 15 2014]
Synthetic Biologics Appoints Prominent Gastroin... [Published InvestorPoint.com - Oct 15 2014]
ContraVir Pharmaceuticals Closes $9.0 Million F... [Published InvestorPoint.com - Oct 15 2014]
What's Up With This Crazy Stock Market? [Published Seeking Alpha - Oct 13 2014]
Synergy Pharmaceuticals : to Present Phase 2b S... [Published 4 Traders - Oct 10 2014]
Synergy Pharmaceuticals to Present Additional P... [Published Finwin - Oct 07 2014]
Synergy Pharmaceuticals to Present Additional P... [Published Business Wire Health News - Oct 07 2014]
SYNERGY PHARMACEUTICALS : Reaches Halfway Mark ... [Published 4 Traders - Sep 25 2014]
Stock Updates on Biotech Industry - Array BioPh... [Published Bio-Medicine - Sep 22 2014]
U.S. Department of Commerce awards $4.2 million... [Published Pennington Post - Sep 19 2014]
Synergy Pharma Reaches Halfway Mark For Second ... [Published RTTNews.com - Sep 18 2014]
Synergy Pharmaceuticals Reaches Halfway Mark fo... [Published Digital Journal - Sep 18 2014]
Synergy Pharmaceuticals Reaches Halfway Mark fo... [Published CEOWorld Magazine - Sep 18 2014]
Synergy Pharmaceuticals Reaches Halfway Mark fo... [Published Business Wire Health News - Sep 18 2014]
Synergy Pharmaceuticals Now Covered by Cowen an... [Published American Banking News - Stock Ratings - Sep 12 2014]
Synergy Pharmaceuticals Reports Second Quarter ... [Published Business Wire Health News - Aug 11 2014]
Synergy Pharmaceuticals to Present at Canaccord... [Published Business Wire Health News - Aug 06 2014]
Synergy closes patient enrollment in Phase II t... [Published PBR - News - Jul 21 2014]
Synergy Pharmaceuticals Completes Patient Enrol... [Published Business Wire Health News - Jul 17 2014]
Synergy Pharmaceuticals Reaches Halfway Mark fo... [Published Business Wire Science: Science News - Jul 14 2014]
Synergy Pharmaceuticals Reaches Halfway Mark fo... [Published Business Wire Health News - Jul 14 2014]
Synergy Pharmaceuticals Announces Successful En... [Published Business Wire Health News - Jul 08 2014]
Synergy Pharmaceuticals’ Chairman and CEO, Dr. ... [Published Business Wire Photo/Multimedia News - May 15 2014]
Synergy Pharmaceuticals’ Chairman and CEO, Dr. ... [Published Business Wire Education News - May 15 2014]
Synergy Pharmaceuticals’ Chairman and CEO, Dr. ... [Published Business Wire Health News - May 15 2014]
Synergy Pharmaceuticals’ Chairman and CEO, Dr. ... [Published Business Wire News with Multimedia - May 15 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Synergy Pharmaceuticals to Present Additional P... [Published Business Wire Health News - Oct 07 2014]
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals to Present Additional Positive Phase 2b Study Results for Plecanatide in Patients with Irritable Bowel Syndrome with Constipation at ACG 2014 Annual Scientific Meeting ...
Synergy Pharmaceuticals Reaches Halfway Mark fo... [Published Business Wire Health News - Sep 18 2014]
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Reaches Halfway Mark for Second Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation ...
Synergy Pharmaceuticals Reports Second Quarter ... [Published Business Wire Health News - Aug 11 2014]
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Reports Second Quarter and First Half 2014 Financial Results ...
Synergy Pharmaceuticals to Present at Canaccord... [Published Business Wire Health News - Aug 06 2014]
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals to Present at Canaccord Genuity Growth Conference ...
Synergy closes patient enrollment in Phase II t... [Published PBR - News - Jul 21 2014]
US-based Synergy Pharmaceuticals has completed patient enrollment in its Phase II trial of SP-333, its next-generation uroguanylin analog, in patients with opioid-induced constipation (OIC). ...
1 2 3 4 5
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.